About Gemelli Biotech
Gemelli Biotech is a company based in Los Angeles (United States) founded in 2018 by Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, and Matt Mitcho. Gemelli Biotech has raised $23.03 million across 3 funding rounds from investors including Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network. Gemelli Biotech offers products and services including Precision Diagnostics. Gemelli Biotech operates in a competitive market with competitors including Oxford MEStar, Chosen Diagnostics, AgPlus Diagnostics, Venaxis and ibs-smart, among others.
- Headquarter Los Angeles, United States
- Founders Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, Matt Mitcho
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gemelli Biotech Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23.03 M (USD)
in 3 rounds
-
Latest Funding Round
$21.18 M (USD), Series A
Dec 07, 2021
-
Investors
Cedars Sinai
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gemelli Biotech
Gemelli Biotech offers a comprehensive portfolio of products and services, including Precision Diagnostics.
Non-invasive tools for detecting biomarkers in GI diseases like SIBO.
People of Gemelli Biotech
Unlock access to complete
Funding Insights of Gemelli Biotech
Gemelli Biotech has successfully raised a total of $23.03M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21.18 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gemelli Biotech
Gemelli Biotech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial-ready healthcare innovators are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Early-stage investment opportunities are facilitated for UNC-affiliated startups.
|
Locked | Locked | Locked | |
|
Early-stage tech companies in Asia and the US are funded.
|
Locked | Locked | Locked |
Investor details for Gemelli Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gemelli Biotech
Investment portfolio details for Gemelli Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gemelli Biotech
Detailed financials for Gemelli Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gemelli Biotech Comparisons
Peer comparison for Gemelli Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gemelli Biotech
Gemelli Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oxford MEStar, Chosen Diagnostics, AgPlus Diagnostics, Venaxis and ibs-smart, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of novel scaffolds for tissue engineering and stem cell delivery
|
|
| Locked | Locked | Locked |
Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants
|
|
| Locked | Locked | Locked |
Portable diagnostic platforms are developed using electrochemistry and nanotechnology.
|
|
| Locked | Locked | Locked |
In vitro diagnostic tests for appendicitis are developed by Venaxis.
|
|
| Locked | Locked | Locked |
Develops and provides at-home blood tests for diagnosing irritable bowel syndrome.
|
Detailed competitors of Gemelli Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gemelli Biotech
Complete news archive for Gemelli Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gemelli Biotech
Gemelli Biotech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Gemelli Biotech is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Matt Mitcho is the current CEO of Gemelli Biotech. They have also founded this company.
Gemelli Biotech is a funded company, having raised a total of $23.03M across 3 funding rounds to date.
Gemelli Biotech was founded in 2018 in Los Angeles, United States, within the biotechnology sector. Diagnostics and therapeutics focused on the human microbiome are developed, often in partnership with Cedars-Sinai Medical Center. Key products include ibs-smart, a blood test for irritable bowel syndrome variants, and sclero-smart, which assesses anti-vinculin antibody levels in systemic sclerosis and scleroderma patients. Further products remain in the pipeline for upcoming releases.
Gemelli Biotech's top competitors include Chosen Diagnostics, AgPlus Diagnostics and Oxford MEStar.
Gemelli Biotech offers Precision Diagnostics.
Gemelli Biotech has 4 investors. Key investors include Cedars Sinai, Blue Ox Healthcare Partners, Carolina Angel Network, and CerraCap Ventures.